Jim Cramer on Insmed: "This One Is Worth Keeping an Eye On"

Insmed Incorporated (NASDAQ:INSM) is one of the S&P 500 and Nasdaq-100 stocks Jim Cramer commented on. Cramer highlighted the stock’s stellar performance for the year and the reason behind it, as he said:

“First there’s one that, jeez, eluded me, it’s called Insmed. That’s a biopharma company that ended last year up 152% for the fifth best performer in the Nasdaq-100. Now, this company is focused on developing drugs for rare diseases and they got an FDA approval from one of their top drug candidates last year. It was a treatment for a lung condition called non-cystic fibrosis bronchiectasis. Now, Wall Street’s bullish because the drug seems to be a powerful anti-inflammatory. And remember, these are what’s known as orphan drugs and they are protected by Congress… a long time ago and been for a long time. Now, Insmed has come down a bit from its highs. The stock pulled back about 18% from its early December peak largely because the drug that just got approved saw a disappointing clinical trial result in chronic sinusitis. Still, this one is worth keeping an eye on. And I admit, I had not been following it until the review. That’s one of the reasons I like these reviews so much. Insmed, didn’t know it. Now I do.”

Insmed Incorporated (NASDAQ:INSM) develops and commercializes treatments for serious and rare diseases, with an approved therapy for complex lung infections and some late and mid-stage clinical programs.

While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.